AstraZeneca stories increased earnings after enhance from robust most cancers drug gross sales
AstraZeneca reported a strong increase in revenue after robust sales of its cancer treatment drugs.
The FTSE 100-listed firm reported that sales and profit rose 8 and 11 per cent, respectively, in line with its forecasts.
It expects total revenue to grow by mid-to-high single-digit percentage, with core profit growth of low double-digit percentage.
It comes as chief executive Pascal Soriot guides the company towards its ambition of reaching $80billion in annual sales by 2030, even as US tariffs and policies remain volatile.
AstraZeneca reported a boost in revenues and profits following strong cancer drug sales
‘The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year,’ said Soriot.
Shares were up 0.5 per cent in early trading.
Cancer treatment drug sales jumped 20 per cent to $7.03billion, around 45 per cent of total revenues, but revenue from cardiovascular drugs slipped 6 per cent to $3.05billion.
Chris Beauchamp, chief market analyst at IG said: ‘The numbers this morning continue to show how AstraZeneca seems to have its house in order when it comes to its drug pipeline.
‘The outlook and recent performance more than justifies the recent surge in the share price which has finally seen it break higher after years of sideways trading.
‘As Novo and others show, it’s not easy to maintain investor interest, but Astra’s broad stable of drugs shows it continues to deliver.’
AstraZeneca said it would raise its annual dividend by 3 per cent to $3.30.
The results are the first since AstraZeneca made its debut on the New York Stock Exchange.
While it is keeping its listings in London and in Stockholm, there have been fears that the drugs giant could switch its main listing to Wall Street.
AstraZeneca makes almost half of its revenues in the US and is targeting further expansion there.
Last July, the company said it plans around £36.5billion in investment in the US by 2030.
DIY INVESTING PLATFORMS
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
